Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08098488 in Advanced Solid Tumors
NCT07903415Phase 1Recruiting
- Sponsor
- Pfizer
- Start
- Oct 2026
- Primary completion
- Jan 2031
- Countries
- 1
01
Overview
Phase 1, open-label trial of PF-08098488 in non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), gastric cancer (GC) and 2 more (3 arms), sponsored by Pfizer. Primary endpoints: Incidence of Adverse Events, Recommended Monotherapy Dose(s) for Expansion at 1 year and 1 more. Started Oct 2026; status: recruiting.
02
Drugs
PF-08098488
03
Conditions
non-small cell lung cancer (NSCLC)pancreatic ductal adenocarcinoma (PDAC)gastric cancer (GC)gastroesophageal junction adenocarcinomaesophageal cancer
Beyond the preview
Go deeper on NCT07903415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07903415.